MarketPulse

cholangiocarcinoma

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Molecular Partners Ag

Molecular Partners' MP0317 Shows Promise in Nature Cancer, Sparks CD40 Agonist Competition

Molecular Partners published positive Phase 1 data for MP0317, a CD40 agonist, in Nature Cancer, demonstrating tumor microenvironment remodeling with favorable safety in advanced cancer patients.
MOLNPhase 1 clinical trialimmunotherapy
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Nuvectis Pharma to Showcase NXP900 Cancer Drug Data at 2026 AACR Meeting

Nuvectis Pharma will present three posters on NXP900, a first-in-class cancer inhibitor, at April's AACR Meeting in San Diego, highlighting combination and immunotherapy potential.
NVCTprecision medicineoncology
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Molecular Partners Posts $61.7M Loss but Funds Pipeline Through 2028

Molecular Partners reports CHF 61.7M net loss but maintains CHF 93.1M cash runway through 2028, advancing Radio-DARPin and immuno-oncology pipeline programs.
MOLNfinancial resultsclinical trial